New consensus offers guidance for management of neonatal lactose intolerance

Lactose is a major carbohydrate in human milk, but breaking it down requires lactase, an intestinal enzyme that can be insufficient in babies born prematurely. In newborns, lactose intolerance is usually linked to digestive immaturity or intestinal injury rather than the rare inherited disorder. Its signs—crying, regurgitation, abdominal swelling and loose stools—also occur in infections, cow's milk protein allergy and dangerous intestinal diseases. Tests designed for older children can be unreliable or impractical in newborns, while unnecessary dietary changes may compromise nutrition. Because accurate diagnosis and feeding choices remain difficult, further systematic investigation is needed to establish consistent approaches to neonatal lactose intolerance.

Published (DOI: 10.1002/pdi3.70044) online on March 27, 2026, in Pediatric Discovery, the consensus was developed by a multidisciplinary group coordinated through the National Clinical Research Center for Child Health and Disorders (Chongqing), with contributors from the Children's Hospital of Chongqing Medical University and other Chinese institutions. Led in its overall design by corresponding author Yuan Shi, the work translates existing evidence and clinical experience into 10 practical recommendations covering symptom recognition, diagnostic testing, differential diagnosis and treatment, particularly for premature infants.

The working group reviewed 61 publications, including randomized controlled trials, observational studies, systematic reviews and earlier guidance. It assessed evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach and applied a modified Delphi process where evidence was limited. The resulting pathway begins with symptoms and stool changes, including unusually acidic-smelling stools. For symptomatic newborns, fecal reducing sugar tests or urinary galactose assays can support initial screening, but neither test alone establishes the diagnosis.

Clinicians should exclude conditions such as necrotizing enterocolitis and cow's milk protein allergy, then consider a supervised diagnostic elimination test, assessing whether symptoms improve with lactase supplementation or reduced lactose intake. For breastfed infants with lactose intolerance, the strongest treatment recommendation is to continue breastfeeding while adding lactase. Formula-fed infants may receive lactase or reduced-lactose formula; lactose-free formula is not recommended as routine first-line or preventive feeding. Treatment generally lasts at least two weeks, with the duration adjusted to clinical recovery. Probiotics producing β-galactosidase are described as possible adjuncts, although neonatal evidence remains limited and safety concerns warrant caution in very premature infants. The guidance also favors lactase preparations with demonstrated safety and efficacy rather than unvalidated products.

The authors said the central message is that feeding decisions should respond to a baby's symptoms and clinical condition, not to an assumption that lactose must always be avoided. They emphasized that the recommendations are intended to help clinicians distinguish lactose intolerance from other causes of feeding distress while preserving the nutritional advantages of human milk. They also cautioned that evidence remains uneven, especially for extremely premature infants and probiotic treatments. The consensus, they said, offers a practical starting point for more consistent care, rather than a substitute for individualized assessment or stronger clinical trials.

For neonatal intensive care teams and pediatric clinicians, the consensus offers a step-by-step framework for deciding when to test, when to intervene and when to reconsider a diagnosis. It may also help families understand why continuing breast milk can be compatible with managing lactose intolerance. Its recommendations apply to newborns and preterm infants below 44 weeks' corrected gestational age, but they are not a universal prescription: severely ill babies and those with rare congenital lactase deficiency require different assessment and management. The authors call for larger randomized controlled trials to clarify treatment timing, long-term outcomes and the safety of probiotics, particularly in the most premature infants.